S Nam, HR Chang, HR Jung, Y Gim, NY Kim,
R Grailhe… - Cancer letters, 2015 - Elsevier
Although trastuzumab is a successful targeted therapy for breast cancer patients with tumors
expressing HER2 (ERBB2), many patients eventually progress to drug resistance. Here, we …